US › Healthcare

ARS Pharmaceuticals, Inc (SPRY)

US · Healthcare · Biotechnology

$4.15-0.36%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$33.7M

Revenue YoY

+114.2%

Net profit

$-62.3M

EPS

$-0.63

EPS estimate

$-0.55

Net margin

-185.2%

EPS came in at -0.63 against a street estimate of -0.55 — a miss of 14.5%.

Key statistics

Market cap

$473.4M

Forward P/E

0.0

P/B

37.71

Book value

$0.13

EPS (TTM)

$-2.18

52-week high

$13.15

52-week low

$4.73

50-day MA

$6.22

200-day MA

$8.52

Beta

1.00

Analyst view

Analysts rate ARS Pharmaceuticals, Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $23.25.

Shareholding

Insiders

16.18%

Institutions

92.08%

Largest institutional holders

Fund	Stake
RA Capital Management, LLC	10.92%
Orbimed Advisors LLC	8.33%
Rubric Capital Management LP	8.04%
Deerfield Management Co	7.55%
BlackRock Inc	5.04%
Tyro Capital Management LLC	4.48%
Aberdeen Group PLC	4.19%
SR ONE CAPITAL MANAGEMENT, LP	4.04%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ARS Pharmaceuticals, Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.